{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:05:05Z","timestamp":1771013105947,"version":"3.50.1"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2011,3,31]],"date-time":"2011-03-31T00:00:00Z","timestamp":1301529600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0014764","type":"journal-article","created":{"date-parts":[[2011,3,31]],"date-time":"2011-03-31T20:53:10Z","timestamp":1301604790000},"page":"e14764","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial"],"prefix":"10.1371","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct00050089","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mark","family":"Holodniy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheldon T.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. William","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tassos C.","family":"Kyriakides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Angus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdel","family":"Babiker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas K.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aslam","family":"Anis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Goodall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fleur","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirek","family":"Piaseczny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Deyton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Darbyshire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the OPTIMA Team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2011,3,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archinte.165.4.416","article-title":"The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.","volume":"165","author":"A d'Arminio Monforte","year":"2005","journal-title":"Arch Intern Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0140-6736(03)13802-0","article-title":"Decline in the AIDS and death rates in the EuroSIDA study: an observational study.","volume":"362","author":"A Mocroft","year":"2003","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1089\/08892220260190308","article-title":"Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.","volume":"18","author":"A Antinori","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0140-6736(99)01122-8","article-title":"Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study.","volume":"353","author":"B Ledergerber","year":"1999","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/135965350100603S03","article-title":"Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.","volume":"6","author":"V Miller","year":"2001","journal-title":"Antivir Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1097\/00002030-199910220-00008","article-title":"Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.","volume":"13","author":"E Race","year":"1999","journal-title":"Aids"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/135965350801300502","article-title":"The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa.","volume":"13","author":"RL Hamers","year":"2008","journal-title":"Antivir Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/01.aids.0000174455.01369.ad","article-title":"Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients.","volume":"19","author":"M Zaccarelli","year":"2005","journal-title":"Aids"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1097\/QAD.0b013e328310e04f","article-title":"Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.","volume":"22","author":"A Cozzi-Lepri","year":"2008","journal-title":"AIDS"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/135965350000500113","article-title":"HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort.","volume":"5","author":"V Miller","year":"2000","journal-title":"Antivir Ther"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00002030-200101050-00010","article-title":"Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens.","volume":"15","author":"JS Montaner","year":"2001","journal-title":"Aids"},{"key":"ref12","first-page":"93","article-title":"Mega-HAART: preliminary results and correlation with baseline resistance.","volume":"4","author":"C Rottmann","year":"1999","journal-title":"Antivir Ther"},{"key":"ref13","first-page":"CD006148","article-title":"Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.","volume":"3","author":"NP Pai","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00002030-200401230-00011","article-title":"Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097).","volume":"18","author":"C Katlama","year":"2004","journal-title":"AIDS"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.qai.0000242450.74779.ee","article-title":"Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study.","volume":"43","author":"J Lawrence","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa035103","article-title":"Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.","volume":"349","author":"J Lawrence","year":"2003","journal-title":"N Engl J Med"},{"key":"ref17","article-title":"Panel on Antiretroviral Guidelines for Adult and A Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.","journal-title":"Department of Health and Human Services"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/jmv.21034","article-title":"Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs.","volume":"80","author":"CF Perno","year":"2008","journal-title":"J Med Virol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/QAI.0b013e3181a4f00d","article-title":"Quality of Life of patients with Advanced HIV\/AIDS: Measuring the Impact of both AIDS Defining Events and Non-AIDS Serious Adverse Events.","volume":"51","author":"AH Anis","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cld.2008.03.009","article-title":"Management complexities of HIV\/hepatitis C virus coinfection in the twenty-first century.","volume":"12","author":"V Lo Re 3rd","year":"2008","journal-title":"Clin Liver Dis"},{"key":"ref21","article-title":"A Predictive Model of Health State Utilities for HIV Patients in the Modern Era of Highly Active Antiretroviral Therapy.","author":"TL Kauf","year":"2008"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1468-1293.2007.00508.x","article-title":"Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004.","volume":"8","author":"F Bonnet","year":"2007","journal-title":"HIV Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.296.7.844","article-title":"Metabolic and skeletal complications of HIV infection: the price of success.","volume":"296","author":"CG Morse","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0197-2456(03)00029-1","article-title":"An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial.","volume":"24","author":"TC Kyriakides","year":"2003","journal-title":"Control Clin Trials"},{"key":"ref25","first-page":"1","article-title":"1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.","volume":"41","year":"1992","journal-title":"MMWR Recomm Rep"},{"key":"ref26","article-title":"Antiretroviral Phenotypic Susceptibility Score as a Predictor of Treatment Response in Persons with Multi-drug-resistant HIV-1.","author":"KH Lawrence J","year":"2006"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/09540120050042891","article-title":"Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG).","volume":"12","author":"MA Chesney","year":"2000","journal-title":"AIDS Care"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/QAI.0b013e31818ce6f3","article-title":"Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease.","volume":"50","author":"VR Joyce","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0197-2456(03)00029-1","article-title":"An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial.","volume":"24","author":"TC Kyriakides","year":"2003","journal-title":"Control Clin Trials"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2008.05.006","article-title":"New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.","volume":"57","author":"A Hughes","year":"2008","journal-title":"J Infect"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e10307","DOI":"10.1371\/journal.pone.0010307","article-title":"A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda.","volume":"5","author":"SJ Reynolds","year":"2010","journal-title":"PLoS One"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0014764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:01:16Z","timestamp":1686009676000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0014764"}},"subtitle":[],"editor":[{"given":"Cheryl A.","family":"Stoddart","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,3,31]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,3,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0014764","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,31]]}}}